ArticleInternal medicine (Tokyo, Japan)2026
A Patient with Pustulotic Arthro-osteitis with Isolated Spinal Lesions Successfully Treated with Risankizumab.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pustulotic arthro-osteitis (PAO) is a rare chronic inflammatory arthropathy associated with palmoplantar pustulosis (PPP). PAO involves various extra-palmoplantar sites, including spinal lesions. Systemic treatment, including biologics, is required for refractory cases of PAO. We herein report a man diagnosed with PAO who predominantly manifested spinal symptoms. Initial treatment with non-steroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and bisphosphonates achieved a minimal response. Risankizumab, an anti-interleukin-23 p19 antibody, was subsequently administered, which resulted in significant improvement after the fourth dose, resolving both spinal and cutaneous manifestations. This case report highlights risankizumab as a potential therapeutic option for refractory PAO with spinal involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.